Perspective Therapeutics, Inc. — Form 8-K
Filed October 1, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Perspective Therapeutics presented clinical and pipeline data for three Phase 1/2a radiopharmaceutical programs: VMT-α-NET (SSTR2+ neuroendocrine tumors), VMT01 (melanoma, MC1R-targeted), and PSV359 (FAP-α solid tumors). VMT-α-NET showed durable disease control across doses with best-in-class safety in n=68 patients; VMT01 demonstrated preliminary anti-tumor activity at 3.0 mCi; PSV359 showed improved tumor retention. All programs target a combined $45B+ addressable market. Company claims decade-long platform engineering and strong IP portfolio; additional clinical data anticipated at ASCO 2026.
Why this rating
Early-stage clinical programs in competitive radiopharmaceutical space; no partnerships, financing, or regulatory milestones announced. Positive Phase 1/2a signals but limited commercial visibility. Moderate relative to $213M market cap.
See more from October 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.